Agilent Technologies (A) | Financial Analysis & Statements
Agilent Technologies Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jan 2026Income Metrics
Revenue
1.8B
Gross Profit
946.0M
52.61%
Operating Income
353.0M
19.63%
Net Income
305.0M
16.96%
EPS (Diluted)
$1.07
Balance Sheet Metrics
Total Assets
12.8B
Total Liabilities
5.9B
Shareholders Equity
6.9B
Debt to Equity
0.85
Cash Flow Metrics
Operating Cash Flow
270.0M
Free Cash Flow
175.0M
Revenue & Profitability Trend
Quarter Income Flow
Jan 31, 2026
Annual Income Flow
2025
Agilent Technologies Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 6.9B | 6.5B | 6.8B | 6.8B | 6.3B |
| Cost of Goods Sold | 3.3B | 3.0B | 3.4B | 3.1B | 2.9B |
| Gross Profit | 3.6B | 3.5B | 3.5B | 3.7B | 3.4B |
| Gross Margin % | 52.4% | 54.3% | 50.7% | 54.4% | 53.9% |
| Operating Expenses | |||||
| Research & Development | 455.0M | 479.0M | 481.0M | 467.0M | 441.0M |
| Selling, General & Administrative | 1.7B | 1.6B | 1.6B | 1.6B | 1.6B |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 2.2B | 2.0B | 2.1B | 2.1B | 2.1B |
| Operating Income | 1.5B | 1.5B | 1.4B | 1.6B | 1.3B |
| Operating Margin % | 21.3% | 22.9% | 19.8% | 23.6% | 21.3% |
| Non-Operating Items | |||||
| Interest Income | 62.0M | 80.0M | 51.0M | 9.0M | 2.0M |
| Interest Expense | 112.0M | 96.0M | 95.0M | 84.0M | 81.0M |
| Other Non-Operating Income | 6.0M | 49.0M | 33.0M | -39.0M | 92.0M |
| Pre-tax Income | 1.4B | 1.5B | 1.3B | 1.5B | 1.4B |
| Income Tax | 132.0M | 232.0M | 99.0M | 250.0M | 150.0M |
| Effective Tax Rate % | 9.2% | 15.3% | 7.4% | 16.6% | 11.0% |
| Net Income | 1.3B | 1.3B | 1.2B | 1.3B | 1.2B |
| Net Margin % | 18.8% | 19.8% | 18.1% | 18.3% | 19.1% |
| Key Metrics | |||||
| EBITDA | 1.8B | 1.9B | 1.7B | 1.9B | 1.8B |
| EPS (Basic) | $4.59 | $4.44 | $4.22 | $4.19 | $3.98 |
| EPS (Diluted) | $4.57 | $4.43 | $4.19 | $4.18 | $3.94 |
| Basic Shares Outstanding | 284000000 | 290000000 | 294000000 | 299000000 | 304000000 |
| Diluted Shares Outstanding | 284000000 | 290000000 | 294000000 | 299000000 | 304000000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Agilent Technologies Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 1.8B | 1.3B | 1.6B | 1.1B | 1.5B |
| Short-term Investments | - | - | - | 0 | 91.0M |
| Accounts Receivable | 1.5B | 1.3B | 1.3B | 1.4B | 1.2B |
| Inventory | 1.0B | 972.0M | 1.0B | 1.0B | 830.0M |
| Other Current Assets | 293.0M | 334.0M | 274.0M | 282.0M | 222.0M |
| Total Current Assets | 4.6B | 4.0B | 4.2B | 3.8B | 3.8B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 9.4B | 9.5B | 8.4B | 8.7B | 8.9B |
| Intangible Assets | 445.0M | 547.0M | 475.0M | 821.0M | 981.0M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.1B | 910.0M | 708.0M | 686.0M | 820.0M |
| Total Non-Current Assets | 8.1B | 7.9B | 6.6B | 6.8B | 6.9B |
| Total Assets | 12.7B | 11.8B | 10.8B | 10.5B | 10.7B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 570.0M | 540.0M | 418.0M | 580.0M | 446.0M |
| Short-term Debt | 304.0M | 45.0M | - | 36.0M | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 2.3B | 1.9B | 1.6B | 1.9B | 1.7B |
| Non-Current Liabilities | |||||
| Long-term Debt | 3.0B | 3.3B | 2.7B | 2.7B | 2.7B |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 463.0M | 578.0M | 477.0M | 536.0M | 659.0M |
| Total Non-Current Liabilities | 3.6B | 4.1B | 3.3B | 3.4B | 3.6B |
| Total Liabilities | 6.0B | 5.9B | 4.9B | 5.2B | 5.3B |
| Equity | |||||
| Common Stock | 3.0M | 3.0M | 3.0M | 3.0M | 3.0M |
| Retained Earnings | 1.4B | 750.0M | 782.0M | 324.0M | 348.0M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 6.7B | 5.9B | 5.8B | 5.3B | 5.4B |
| Key Metrics | |||||
| Total Debt | 3.4B | 3.4B | 2.7B | 2.8B | 2.7B |
| Working Capital | 2.2B | 2.1B | 2.6B | 1.9B | 2.1B |
Balance Sheet Composition
Agilent Technologies Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.3B | 1.3B | 1.2B | 1.3B | 1.2B |
| Depreciation & Amortization | 288.0M | 257.0M | 271.0M | 317.0M | 321.0M |
| Stock-Based Compensation | 128.0M | 129.0M | 111.0M | 125.0M | 110.0M |
| Working Capital Changes | -131.0M | 83.0M | -116.0M | -478.0M | -102.0M |
| Operating Cash Flow | 1.5B | 1.7B | 1.5B | 1.2B | 1.6B |
| Investing Activities | |||||
| Capital Expenditures | -407.0M | -378.0M | -298.0M | -291.0M | -187.0M |
| Acquisitions | 4.0M | -862.0M | -1.0M | -52.0M | -547.0M |
| Investment Purchases | 0 | -5.0M | -8.0M | -13.0M | -22.0M |
| Investment Sales | 8.0M | 0 | 5.0M | 22.0M | 12.0M |
| Investing Cash Flow | -394.0M | -1.3B | -310.0M | -338.0M | -749.0M |
| Financing Activities | |||||
| Share Repurchases | -425.0M | -1.2B | -575.0M | -1.1B | -788.0M |
| Dividends Paid | -282.0M | -274.0M | -265.0M | -250.0M | -236.0M |
| Debt Issuance | 4.0M | 1.2B | 0 | 600.0M | 848.0M |
| Debt Repayment | -3.0M | -600.0M | 0 | -609.0M | -417.0M |
| Financing Cash Flow | -787.0M | -829.0M | -997.0M | -1.4B | -751.0M |
| Free Cash Flow | 1.2B | 1.4B | 1.5B | 1.0B | 1.3B |
| Net Change in Cash | 327.0M | -349.0M | 190.0M | -532.0M | 64.0M |
Cash Flow Trend
Agilent Technologies Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
25.67
Forward P/E
17.67
Price to Book
4.76
Price to Sales
4.65
PEG Ratio
-7.19
Profitability Ratios
Profit Margin
18.26%
Operating Margin
22.86%
Return on Equity
19.95%
Return on Assets
8.53%
Financial Health
Current Ratio
2.07
Debt to Equity
51.39
Beta
1.30
Per Share Data
EPS (TTM)
$4.53
Book Value per Share
$24.44
Revenue per Share
$24.92
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| A | 32.7B | 25.67 | 4.76 | 19.95% | 18.26% | 51.39 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Idexx Laboratories | 44.7B | 42.92 | 27.85 | 66.20% | 24.62% | 60.83 |
| Waters | 30.5B | 28.90 | 7.24 | 29.28% | 20.30% | 60.28 |
| Natera | 27.4B | - | 15.75 | -14.32% | -9.03% | 12.52 |
Financial data is updated regularly. All figures are in the company's reporting currency.






